Procept (PRCT): 50% rise on high volume. Why? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?

PRCT 28.96

-0.5%

Jan 30 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gerald Thomas who wrote (229)	8/7/1997 10:53:00 AM
From: Douglas	of 455

In response to your comments: Repligen may have not been a good mention as an acquisition candidate, but I still believe that Paramount Capital has more planned for Procept then just financial support. They hope to make money on their investment. Only time will tell what they have planned. Controlling the Board of Directors means that they can control the strategic planning and the direction of the company. I would have to disagree with you that Procept is primarily PRO 2000. I'm much more positive now. I see the current price as a buying opportunity. When the little investor realizes that, it will be too late, the stock price will spike and the little investor will only be able to buy at the top. I'm not talking a big increase, just over $1.00. I still like the caparison with Repligen. Repligen redirected its focus in 1996. They are a small company (15 employees) involved with the development of enabling technology for the discovery of new drugs (combinatorial chemistry and screening technologies). Repligen has focused on autoimmune diseases. Their stock was trading below 50 cents last year. Paramount Capital has invested their money. They have about 17,000,000 shares outstanding. Preferred stock was approved, but not used yet. Everything mentioned above applies to Procept! Their balance sheet looks very similar to Procept. Repligen's stock is trading at about $1.25. Is Repligen overvalued? I think not. I see Procept has having the potential to benefit from drug discovery collaborations using its combinatorial chemistry, PRO 2000 licenses and royalties, autoimmune disease research, and tuberculosis study. Definitely not PRO 2000 only. Before Paramount Capital invested their money, they did a complete review of Procept and must have seen something they liked or they wouldn't have invested. Efficacy is important and hopefully we will see some mention in Phase II next year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next